Compare · FDMT vs MRNA
FDMT vs MRNA
Side-by-side comparison of 4D Molecular Therapeutics Inc. (FDMT) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FDMT and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 42.7x FDMT ($574.5M).
- Over the past year, FDMT is up 159.3% and MRNA is up 99.5% - FDMT leads by 59.8 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 8 for FDMT).
- MRNA has more recent analyst coverage (25 ratings vs 18 for FDMT).
- Company
- 4D Molecular Therapeutics Inc.
- Moderna Inc.
- Price
- $10.98+1.48%
- $61.80-2.14%
- Market cap
- $574.5M
- $24.53B
- 1M return
- +26.79%
- +11.57%
- 1Y return
- +159.27%
- +99.48%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 8
- 10
- Recent ratings
- 18
- 25
4D Molecular Therapeutics Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest FDMT
- 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
- 4DMT Announces New Employment Inducement Grants
- Officer Kirn David sold $737,410 worth of shares (58,333 units at $12.64) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 884,152 units (SEC Form 4)
- Chief Legal Officer Bizily Scott sold $91,924 worth of shares (6,566 units at $14.00) as part of a pre-agreed trading plan and exercised 6,566 shares at a strike of $6.20 (SEC Form 4)
- 4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
- 4D Molecular Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
- 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
- Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
- Chief Legal Officer Bizily Scott exercised 9,810 shares at a strike of $4.14 and sold $117,720 worth of shares (9,810 units at $12.00) (SEC Form 4)
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester